SARS Pneumonia

22 registered clinical trials studyying SARS Pneumonia.

Status	Trial	Sponsor	Phase
Withdrawn	Characteristics of Patients With COVID-19 in Meta State, Colombia NCT04456426	Hospital Departamental de Villavicencio	—
Completed	Follow-up of Covid-19 Long Term Sequelae NCT05097677	Azienda Ospedaliera Universitaria Integrata Verona	—
Completed	Infection Control for Severe Acute Respiratory Syndrome Coronavirus 2 NCT04665960	NMC Specialty Hospital	—
Completed	Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety o NCT04629703	Rigel Pharmaceuticals	Phase 3
Completed	Assess the Safety and Immunogenicity of NDV-HXP-S Vaccine in Thailand NCT04764422	Mahidol University	Phase 1 / Phase 2
Completed	A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC (Phase 1) NCT04830800	Institute of Vaccines and Medical Biologicals, Vietnam	Phase 1
Unknown	Effectiveness of Niclosamide as Add-on Therapy to the Standard of Care Measures in COVID-19 Management NCT04753619	University of Baghdad	Phase 2
Completed	Efficacy of Vitamin D Treatment in Mortality Reduction Due to COVID-19. NCT04621058	Bioaraba Health Research Institute	Phase 3
Completed	Dysphagia and Dysphonia Outcomes in SARS CoV-2 (COVID-19) Infection (DYADS Study) NCT04584658	Cambridge University Hospitals NHS Foundation Trust	—
Terminated	Cardiovascular Implications of COVID-19 NCT04435457	University of Texas Southwestern Medical Center	—
Withdrawn	A Study of Combination Therapies to Treat COVID-19 Infection NCT04459702	ProgenaBiome	Phase 2
Terminated	Glycine Supplement for Severe COVID-19 NCT04443673	Instituto Nacional de Enfermedades Respiratorias	N/A
Unknown	Baricitinib Compared to Standard Therapy in Patients With COVID-19 NCT04393051	Azienda Ospedaliero, Universitaria Pisana	Phase 2
Completed	Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial NCT04405310	Grupo Mexicano para el Estudio de la Medicina Intensiva	Phase 2
Completed	Long Term Functional Outcomes of COVID-19 Patients Treated by Rehabilitation Services viaTelehealth NCT04385901	University of Missouri-Columbia	N/A
Terminated	Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers NCT04403685	Beneficência Portuguesa de São Paulo	Phase 3
Completed	Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia NCT04374565	University of Virginia	Phase 2
Completed	Respiratory Mechanics and Gas Exchange in Patients With COVID-19 and Hypoxemic Acute Respiratory Failure NCT04445961	I.M. Sechenov First Moscow State Medical University	—
Completed	Anxiety and Work Resilience Among Tertiary University Hospital Workers During the COVID-19 Outbreak: An Online NCT04358640	Centre Hospitalier Universitaire de Nīmes	—
Completed	The Effects of Pulmonary Physiotherapy Treatments on Patients With COVID-19 NCT04357340	Tehran University of Medical Sciences	N/A
Unknown	Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis NCT04315480	Università Politecnica delle Marche	Phase 2
Withdrawn	A Study of ResCure™ to Treat COVID-19 Infection NCT04395716	ProgenaBiome	Phase 1